Herbal compositions comprising dihydromyricetin (DHM) and methods of use. The herbal compositions include DHM in combination with other ingredients to form compositions that can significantly improve the quality and duration of sleep, reduce the time for onset of improved sleep quality and duration, and treat or alleviate the symptoms of sleep-related disorders and neurological conditions. The composition is a therapeutic alternative to drugs to alleviate sleep disorders and related symptoms and ailments.

Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating microbial infections, and methods for treating microbial infections by topically administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the patient in need of treatment.

Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating microbial infections, and methods for treating microbial infections by topically administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the patient in need of treatment.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

In an aspect of the present application, a composition for preventing or treating skin damage in skin of a mammalian subject in need thereof can include at least one autophagy promoter and at least one diuretic. The at least one autophagy promoter and the at least one diuretic, in combination, can each be present in an amount sufficient to prevent or treat the skin damage. In another aspect, the present application includes a method for preventing or treating skin damage in skin of a mammalian subject in need thereof whereby the composition can be administered to the subject in a therapeutically effective amount to prevent or treat the skin damage.

In an aspect of the present application, a composition for preventing or treating skin damage in skin of a mammalian subject in need thereof can include at least one autophagy promoter and at least one diuretic. The at least one autophagy promoter and the at least one diuretic, in combination, can each be present in an amount sufficient to prevent or treat the skin damage. In another aspect, the present application includes a method for preventing or treating skin damage in skin of a mammalian subject in need thereof whereby the composition can be administered to the subject in a therapeutically effective amount to prevent or treat the skin damage.

In an aspect of the present application, a composition for preventing or treating skin damage in skin of a mammalian subject in need thereof can include at least one autophagy promoter and at least one diuretic. The at least one autophagy promoter and the at least one diuretic, in combination, can each be present in an amount sufficient to prevent or treat the skin damage. In another aspect, the present application includes a method for preventing or treating skin damage in skin of a mammalian subject in need thereof whereby the composition can be administered to the subject in a therapeutically effective amount to prevent or treat the skin damage.

Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.